@article {1478344,
	title = {Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases},
	journal = {J Immunol},
	volume = {203},
	number = {11},
	year = {2019},
	month = {2019 Dec 01},
	pages = {2749-2755},
	abstract = {Regulatory T cells (Tregs) play a central role in the induction and maintenance of immune homeostasis and self-tolerance. Tregs constantly express the high-affinity receptor to IL-2. IL-2 is a pleiotropic cytokine and a key survival factor for Tregs. It maintains Tregs{\textquoteright} suppressive function by promoting Foxp3 expression and subsequent production of immunoregulatory cytokines. Administration of low-dose IL-2 is shown to be a promising approach to prevent allograft rejection and to treat autoimmune and inflammatory conditions in experimental models. The combination of IL-2 with its mAb (JES6-1) has also been shown to increase the of IL-2 and further enhance Treg frequencies and function. Low-dose IL-2 therapy has been used in several clinical trials to treat conditions such as hepatitis C vasculitis, graft-versus-host disease, type 1 diabetes, and systemic lupus erythematosus. In this paper, we summarize our findings on low-dose IL-2 treatment in corneal allografting and review recent studies focusing on the use of low-dose IL-2 in transplantation, autoimmunity, and other inflammatory conditions. We also discuss potential areas of further investigation with the aim to optimize current low-dose IL-2 regimens.},
	issn = {1550-6606},
	doi = {10.4049/jimmunol.1900733},
	author = {Tahvildari, Maryam and Dana, Reza}
}
